Stephen Griffin is President and Chief Executive Officer; Former EVP, Chief Financial Officer and Chief Operating Officer of Anika Therapeutics, Inc. (ANIK). The company reported total compensation of $2,033,370 for fiscal year 2025.
| Salary | $500,000 |
|---|---|
| Bonus | $300,000 |
| Stock awards | $1,215,222 |
| Option awards | $0 |
| Non-equity incentive plan | $0 |
| Pension and non-qualified deferred compensation | $0 |
| All other compensation | $18,148 |
| Total | $2,033,370 |
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed, without adjustment.
Cited to the compensation disclosure Anika Therapeutics, Inc. filed April 28, 2026, accession 0001140361-26-017488.
| Named executive officer | Role | FY2025 total |
|---|---|---|
| Cheryl Blanchard | Executive Chair; Former President and Chief Executive Officer | $4,887,318 |
| Stephen Griffin this page | President and Chief Executive Officer; Former EVP, Chief Financial Officer and Chief Operating Officer | $2,033,370 |
| David Colleran | Executive Vice President, General Counsel and Secretary | $1,614,205 |
| Anne Nunes | Former Senior Vice President, Chief Operations Officer | $946,571 |
| Ian McLeod | Senior Vice President, Chief Accounting Officer and Treasurer | $765,544 |
The company's named executive officers for fiscal year 2025, and what it reported for each. See the full Anika Therapeutics, Inc. compensation brief.
Stephen Griffin's compensation sits inside Anika Therapeutics, Inc.'s full executive and board picture — the peer group, pay against peers, incentive design and the board itself.